Immuneering To Present Phase 2a Trial Data For IMM-1-104 In First-Line And Second-Line Pancreatic Cancer, Along With Phase 1 Data For IMM-6-415, At Virtual Investor Event In January 2025
Immuneering To Present Phase 2a Trial Data For IMM-1-104 In First-Line And Second-Line Pancreatic Cancer, Along With Phase 1 Data For IMM-6-415, At Virtual Investor Event In January 2025
Immuneering將在2025年1月的虛擬投資者活動中,展示IMm-1-104在一線和二線胰腺癌的2a期臨床試驗數據,以及IMm-6-415的1期數據。
Immuneering To Present Phase 2a Trial Data For IMM-1-104 In First-Line And Second-Line Pancreatic Cancer, Along With Phase 1 Data For IMM-6-415, At Virtual Investor Event In January 2025
Immuneering將在2025年1月的虛擬投資者活動中,展示IMm-1-104在一線和二線胰腺癌的2a期臨床試驗數據,以及IMm-6-415的1期數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。